[1-[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]piperidin-4-yl]-[4-(2-pyridin-2-ylimidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]methanone | 618897-43-1

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: [1-[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]piperidin-4-yl]-[4-(2-pyridin-2-ylimidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]methanone
• CAS: 618897-43-1
• 化学式: C₃₀H₃₇N₇O₂
• 分子量: 527.669
• InChiKey: AWNFUQZEIFYWED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  83.5
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• (1-4-PIPERIDINYL)BENZIMIDAZOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS
  申请人：Schering Corporation

  公开号：EP1499316B1

  公开（公告）日：2008-03-19
• Combination of an H3 antagonist/inverse agonist and an appetite suppressant
  申请人：van Heek Margaret

  公开号：US20070142369A1

  公开（公告）日：2007-06-21

  The present invention relates to pharmaceutical compositions comprising therapeutic combinations comprising: one or more H 3 antagonists/inverse agonists; one or more appetite suppressants selected from the group consisting of CB 1 antagonists/inverse agonists, sibutramine, phentermine and topiramate; and optionally one or more HMG-CoA reductase inhibitors. The invention also relates to medicaments and kits comprising the pharmaceutical compositions of the present invention, and methods of treating obesity, obesity related disorders and diabetes using the pharmaceutical compositions of the present invention.
• BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Aslanian Robert G.

  公开号：US20100144591A1

  公开（公告）日：2010-06-10

  The present invention relates to compounds of formula (I); compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IGT) in a patient.
• [EN] COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT<br/>[FR] COMBINAISON D'UN ANTAGONISTE/AGONISTE INVERSE DE H3 ET D'UN MODERATEUR DE L'APPETIT
  申请人：SCHERING CORP

  公开号：WO2007075555A2

  公开（公告）日：2007-07-05

  [EN] The present invention relates to pharmaceutical compositions comprising therapeutic combinations comprising: one or more H3 antagonists/inverse agonists; one or more appetite suppressants selected from the group consisting of CBi antagonists/inverse agonists, sibutramine, phentermine and topiramate; and option one or more HMG-CoA reductase inhibitors. The invention also relates to medicaments and kits comprising the pharmaceutical compositions of the present invention, and methods of treating obesity, obesity related disorders and diabetes using the pharmaceutical compositions of the present invention.
  [FR] La présente invention concerne des compositions pharmaceutiques comprenant les combinaisons thérapeutiques suivantes : un ou plusieurs antagonistes/agonistes inverses de H3 ; un ou plusieurs modérateurs de l'appétit choisis dans le groupe comprenant des antagonistes/agonistes inverses de CBi, la sibutramine, la phentermine et le topiramate ; et facultativement un ou plusieurs inhibiteurs de la HMG-CoA réductase. L'invention concerne également des médicaments et des kits comprenant les compositions pharmaceutiques de la présente invention et des procédés de traitement de l'obésité, des troubles liés à l'obésité et du diabète à l'aide des compositions pharmaceutiques de la présente invention.